A genome-wide host-directed screening study published in npj Viruses identifies both antiviral drug candidates and cellular signaling pathways that SARS-CoV-2 appears to exploit during infection. By using the host genome as the experimental “target space,” the approach shifts attention away from viral proteins alone toward host machinery. The report describes how genome-scale interrogation can surface host factors tied to pro-viral pathways, which may become targets for combination strategies that reduce resistance risk. It also highlights how such screens can generate candidate interventions beyond direct viral inhibition. For antiviral R&D teams, the work provides a blueprint for scaling target discovery using host biology rather than relying exclusively on viral genomics.